secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001628280-25-044828
Event type: litigation
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

Allogene reports patent infringement lawsuit against licensor Cellectis by Factor Bioscience
--------------------------------------------------------------------------------

- Factor Bioscience filed a complaint in Delaware against Cellectis and AstraZeneca on Sept 26, 2025, alleging TALEN gene-editing patent infringement.
- Allogene relies on Cellectis's TALEN technology for allogeneic CAR T candidates including cema-cel and ALLO-316.
- Cellectis notified Allogene on October 6, 2025, and intends to vigorously defend against the claims.
- Factor may also assert direct claims against Allogene as a commercial user of the disputed technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000162828025044828/0001628280-25-044828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000162828025044828/allo-20250926.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-044828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer